Analysts Offer Insights on Healthcare Companies: Nabriva (ALDR) and Alder Biopharmaceuticals (ALDR)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nabriva (NASDAQ: NBRV) and Alder Biopharmaceuticals (NASDAQ: ALDR) with bullish sentiments.

Nabriva (NASDAQ: NBRV)

Needham analyst Alan Carr assigned a Buy rating to Nabriva (NASDAQ: NBRV) today and set a price target of $18. The company’s shares opened today at $4.53, close to its 52-week low of $4.39.

Carr observed:

“Nabriva announced results from the second of two Phase 3 trials in Community Pneumonia (CABP) earlier today. Both FDA and EMA non- inferiority primary endpoints were met against comparator moxifloxacin. Safety and tolerability profile appears consistent w/ prior clinical trial data, although we note a higher incidence of primarily mild GI adverse events. We do not believe GI profile is sufficiently concerning to impact physician willingness to prescribe. Mgmt guided for NDA submission 4Q18. Overall, we view the Phase 3 program outcome as favorable and expect the drug to be approved mid-2019. We believe the unmet need in CABP and the unique suitability of lefamulin for this indication is underappreciated by investors. Peak sales in the hospital is likely modest, but we believe lefamulin can be relevant in the large outpatient community setting.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.6% and a 43.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on Nabriva is Strong Buy and the average price target is $16, representing a 253.2% upside.

In a report issued on May 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $16 price target.

See today’s analyst top recommended stocks >>

Alder Biopharmaceuticals (NASDAQ: ALDR)

Canaccord Genuity analyst Sumant Kulkarni assigned a Buy rating to Alder Biopharmaceuticals (NASDAQ: ALDR) today and set a price target of $20. The company’s shares opened today at $15.10.

According to TipRanks.com, Kulkarni is a 1-star analyst with an average return of -0.5% and a 47.9% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Intra-Cellular Therapies, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Alder Biopharmaceuticals is Strong Buy and the average price target is $22.67, representing a 50.1% upside.

In a report issued on May 9, BMO Capital also maintained a Buy rating on the stock with a $21 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts